Monthly research recap
Ibogaine research: June 2026
What June 2026's 6 new studies found, synthesized from the papers below. All Ibogaine research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ibogaine, iboga, noribogaine, then ranked by relevance.
Research on ibogaine in June 2026 shows that treatment-associated mortality is largely confined to opioid detoxification and rare in non-SUD indications, based on a large multisite analysis of 19,071 patients. A case series suggests potential benefits for brain injury syndromes, but safety concerns (especially cardiac risk) remain the main limitation, and no randomized controlled trials were reported. The evidence is insufficient to draw firm conclusions about efficacy due to the lack of controlled trials and reliance on observational and preclinical data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| MiSAM opposes bill giving $50 million in opioid settlement funds to ibogaine research 2026 | policy statement | Unclear | The Michigan Society of Addiction Medicine opposed a bill allocating $50 million in opioid settlement funds to ibogaine research, reflecting concerns about the evidence base. | |
| Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain. 2026 | preclinical analytical method development | Unclear | A validated UPLC-MS/MS method was developed to quantify iboga alkaloids in rat brain microdialysate, enabling future neuropharmacokinetic studies. | |
| Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities 2026 | retrospective multisite analysis with systematic review | 19071 | Mixed | Ibogaine-associated mortality was largely confined to opioid detoxification (6 deaths among 10,382 opioid use disorder patients) and rare in non-SUD indications (0 deaths among 8,689 patients), with the systematic review confirming 41/44 fatalities involved SUD. |
| Physarum-Mediated Biofeedback Rehabilitation: A Bio-Hybrid Framework for Ibogaine-Assisted Neural Recovery 2026 | defensive publication (theoretical framework) | Unclear | A bio-hybrid framework for ibogaine-assisted neural recovery using Physarum-mediated biofeedback was proposed, but no empirical data were provided. | |
| Uso da ibogaína no tratamento da dependência química: uma revisão de literatura 2026 | literature review | Mixed | The review found that ibogaine shows multimodal pharmacological action and observational evidence of reduced withdrawal and craving, but safety remains the main limitation due to risk of QT prolongation and cardiac events. | |
| Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series 2026 | case series | 3 | Supports | An integrative iboga microdosing protocol combined with psychotherapy was associated with clinical improvement in neurological and cognitive symptoms in all three participants. |
Points of agreement
- Ibogaine shows therapeutic potential for substance use disorders and possibly other conditions.
- Safety concerns, particularly cardiac arrhythmia risk, are a major limitation across studies.
- Mortality risk appears concentrated in opioid detoxification settings.
Conflicts
- The policy statement (article 27243) reflects opposition to funding ibogaine research, while the clinical studies suggest potential benefits, indicating disagreement about the readiness of the evidence for large-scale investment.
- The case series (article 27255) reports positive outcomes for brain injury, but the large safety study (article 27250) did not include such patients, so generalizability is unclear.
Gaps
- No randomized controlled trials were reported in June 2026.
- Durability of effects beyond short-term follow-up is not addressed.
- Blinding and placebo controls are absent in the clinical studies.
- Specific populations (e.g., non-SUD indications, brain injury) are understudied.
- Dose-response relationships and optimal protocols are not established.